Targeting the extra domain A of fibronectin for cancer therapy with CAR-T cells (vol 10, e004479corr1, 2022)

被引：1
|
作者：
Martin-Otal, C. [1 ]
Lasarte-Cia, A.
Serrano, D.
机构：
[1] Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2022年 / 10卷 / 09期
关键词：
D O I：
10.1136/jitc-2021-004479corr1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 49 条
  • [21] Construction of CAR-T cells targeting TM4SF1 and its anti-tumor capacity in ovarian cancer
    Shen, Yijie
    Liu, Guodi
    Zhang, Qian
    Tian, Xiaoli
    Ouyang, Liming
    Zhang, Lixin
    IMMUNOLOGY LETTERS, 2023, 255 : 1 - 9
  • [22] CS1 CAR-T targeting the distal domain of CS1 (SLAMF7) shows efficacy in high tumor burden myeloma model despite fratricide of CD8+CS1 expressing CAR-T cells
    O'Neal, Julie
    Ritchey, Julie K.
    Cooper, Matthew L.
    Niswonger, Jessica
    Sofia Gonzalez, L.
    Street, Emily
    Rettig, Michael P.
    Gladney, Susan W.
    Gehrs, Leah
    Abboud, Ramzi
    Prior, Julie L.
    Haas, Gabriel J.
    Jayasinghe, Reyka G.
    Ding, Li
    Ghobadi, Armin
    Vij, Ravi
    DiPersio, John F.
    LEUKEMIA, 2022, 36 (06) : 1625 - 1634
  • [23] CS1 CAR-T targeting the distal domain of CS1 (SLAMF7) shows efficacy in high tumor burden myeloma model despite fratricide of CD8+CS1 expressing CAR-T cells
    Julie O’Neal
    Julie K. Ritchey
    Matthew L. Cooper
    Jessica Niswonger
    L. Sofía González
    Emily Street
    Michael P. Rettig
    Susan W. Gladney
    Leah Gehrs
    Ramzi Abboud
    Julie L. Prior
    Gabriel J. Haas
    Reyka G. Jayasinghe
    Li Ding
    Armin Ghobadi
    Ravi Vij
    John F. DiPersio
    Leukemia, 2022, 36 : 1625 - 1634
  • [24] CAR T Cells Targeting the Tumor MUC1 Glycoprotein Reduce Triple-Negative Breast Cancer Growth (vol 10, 1149, 2019)
    Zhou, Ru
    Yazdanifar, Mahboubeh
    Roy, Lopamudra Das
    Whilding, Lynsey M.
    Gavrill, Artemis
    Maher, John
    Mukherjee, Pinku
    FRONTIERS IN IMMUNOLOGY, 2020, 11
  • [25] Publisher Correction: Manufacturing and preclinical validation of CAR T cells targeting ICAM-1 for advanced thyroid cancer therapy
    Yogindra Vedvyas
    Jaclyn E. McCloskey
    Yanping Yang
    Irene M. Min
    Thomas J. Fahey
    Rasa Zarnegar
    Yen-Michael S. Hsu
    Jing-Mei Hsu
    Koen van Basien
    Ian Gaudet
    Ping Law
    Nak Joon Kim
    Eric von Hofe
    Moonsoo M. Jin
    Scientific Reports, 10
  • [26] Assessment and predictive ability of the absolute neutrophil count in peripheral blood for in vivo CAR T cells expansion and CRS(vol 11, e007790corr1, 2023]
    Zhang, Man
    Long, Xiaolu
    Xiao, Yi
    Liu, Aichun
    Chen, Liting
    RMD OPEN, 2023, 11 (12):
  • [27] Clinical manufacturing of CAR T cells targeting ICAM-1 for a phase I study against advanced thyroid cancer therapy
    Vedvyas, Yogindra
    McCloskey, Jaclyn E.
    Yang, Yanping
    Min, Irene M.
    Fahey, Thomas J.
    Hsu, Yen-Michael S.
    Hsu, Jing-Mei
    Besien, Koen V.
    Gaudet, Ian
    Law, Ping
    Kim, Joon
    Hofe, Eric V.
    Jin, Moonsoo M.
    CANCER RESEARCH, 2019, 79 (13)
  • [28] Structural insights into engineering a T-cell receptor targeting MAGE-A10 with higher affinity and specificity for cancer immunotherapy (vol 10, e004600, 2022)
    Simister, P. C.
    Border, E. C.
    Vieira, J. F.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (09)
  • [29] NOVEL CRISPR/CAS9-BASED ALLOGENEIC CAR-T CELLS TARGETING NKG2D LIGANDS: A POTENTIAL UNIVERSAL CELL THERAPY AGAINST CANCER
    Aparicio, C.
    Belver, M.
    Espeso, F.
    Enriquez, L.
    Perez, J. Serna
    Valeri, A.
    Leivas, A.
    Powell, D. J., Jr.
    Garcia-Sancho, J.
    Martinez-Lopez, J.
    Sanchez, A.
    De la Fuente, M. A.
    Gonzalez-Vallinas, M.
    HUMAN GENE THERAPY, 2022, 33 (7-8) : A28 - A28
  • [30] PD-L1 CAR effector cells induce self-amplifying cytotoxic effects against target cells (vol 10, e002500, 2022)
    Bajor, M.
    Graczyk-Jarzynka, A.
    Marhelava, K.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (03)
12345